Scientific presentations including slides, posters and abstracts
Knezovich N, Thiel JK, Lizama BN, et al. Sigma-2 receptor modulators including CT1812 modulate low density lipoprotein uptake in primary rat neurons. Poster presented at Keystone 2025; Whistler, BC, Canada
Thiel JK, Cho E, Caggiano AO, et al. CT1812 preserves neurons and decreases levels of neurodegeneration biomarker NfL in disease-relevant neuronal model. Poster presented at Keystone 2025; Whistler, BC, Canada
Cho E, Thiel JK, Caggiano AO, et al. The sigma-2 receptor modulator and investigational therapeutic CT1812 is neuroprotective against 4-HNE-induced cell death in a disease-relevant neuronal model. Poster presented at Keystone 2025; Whistler, BC, Canada
Lizama BN, Reaver A, Di Caro V, et al. Delineating Mechanisms of Sigma-2 Receptor Modulators in Regulating Retinal Pigment Epithelial Lipid Uptake. Poster presented at ARVO 2025; Salt Lake City, UT
Hamby ME, Lizama BN, Reaver A, et al. Sigma-2 Receptor Modulation Promotes Retinal Pigment Epithelial Cell Survival Following Chronic 7-Ketocholesterol Exposure. Poster presented at ARVO 2025; Salt Lake City, UT
Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients. Poster presented at AD/PD 2025; Vienna, Austria
Di Caro V, Cho E, Lizama B, et al. Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Galvin JE, Tolea MI, Fargo KN, et al. Results from COG1201: A Proof-of-Concept Study of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies. Slides presented at International Lewy Body Dementia Conference (ILBDC) 2025; Amsterdam, The Netherlands
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
